Form 4 for INMB Inmune Bio, Inc.

Accepted 2024-09-16 00:00:00 ET · period of report 2024-09-12 · accession 0001213900-24-079119 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-09-16	2024-09-12	INMB	Moss David J	CFO, 10%	P - Purchase	$6.38	+7,690	1.28M	+0.6%	+$49.1K
D	2024-09-16	2024-09-12	INMB	Moss David J	CFO, 10%	P - Purchase	$0.13	+7,690	7,690	New	+$999.70

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-09-12	P	A	7,690	$6.38	1,275,869	D	—	—
2	Derivative	Common Stock Warrants (right to buy)	2024-09-12	P	A	7,690	$0.13	7,690	D	$6.40 · — to 2030-03-16	7,690 Common Stock	(F1) The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $6.50, for an aggregate purchase price of $13,000,000 pursuant to a securities purchase agreement dated September 12, 2024. The Warrants are exercisable on or after March 16, 2025 and will terminate on March 16, 2030 unless such termination is accelerated pursuant to the terms of the Warrants (the "Termination Date"), provided, however, in the event that the Warrant is held by Insiders and the Termination Date is during a period that such Insiders are subject to a blackout with respect to trading in the Company's common stock, such Insiders will have an additional 60 days from the termination of the blackout to exercise the Warrant. The exercise price the Warrants is $6.40 per share subject to adjustment as provided in the Warrant.